Synphatec is a Shanghai-based biopharmaceutical company founded in 2021 that develops next-generation therapies for central nervous system (CNS) disorders, including depression and Alzheimer's disease. Its pipeline spans seven programs built on two internal drug-discovery platforms, i-NaS and SynX, led by SP-101, a rapid-acting NMDA-receptor-targeted antidepressant that has completed Phase I, and SP-201, an amyloid-beta gene therapy approaching investigator-initiated trials. The company operates within the Johnson & Johnson JLABS network, with a JLABS Singapore base and a virtual residency, and focuses on neuropsychiatry.
1
Round
1
Industry
5
Tags
Sep 27, 2026
Latest raise
Funding activity · 1 round
Sep 27, 2026
$50M
Series A
Led by Decheng Capital
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
